Table 3.
Multiple logistic regression-deriveda odds ratios (ORs) and 95% confidence intervals (CIs) for breast cancer versus benign breast disease (BBD, overall and by receptor status) per standard deviation increase in insulin-like growth factor 1 (IGF-1) levels
| All women |
Pre-menopausal women |
Post/peri-menopausal women |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| n | OR (95%CI) | P-value | n | OR (95%CI) | P-value | n | OR (95%CI) | P-value | |
| Cancer ERα(+) versus all BBD | 102 versus 261 | 1.36 (0.95–1.94) | 0.099 | 28 versus 171 | 1.47 (0.79–2.73) | 0.226 | 74 versus 90 | 1.33 (0.85–2.08) | 0.214 |
| Cancer ERα(+) versus BBD ERα(+) | 102 versus 178 | 1.95 (1.31–2.89) | 0.001 | 28 versus 108 | 1.88 (0.93–3.81) | 0.080 | 74 versus 70 | 2.61 (1.35–5.06) | 0.004 |
| Cancer ERα(+) versus BBD ERα(−) | 102 versus 83 | 0.81 (0.52–1.26) | 0.347 | 28 versus 63 | 0.95 (0.46–1.98) | 0.897 | 74 versus 20 | 0.76 (0.46–1.25) | 0.275 |
aControlling for age, menopausal status (in the analyses for all women), day of the cycle among pre-menopausal women, IGFBP-3 and hormone use (oral contraceptive use among pre-menopausal women and hormone replacement treatment among post-menopausal women).